A message from the President…
Cancer, when not a statistic in the newspaper or a neighbor down the street, takes on a personal meaning if it becomes your diagnosis or that of a loved one. Bladder cancer has a greater than 50% recurrence rate and, although it is the 6th most prevalent cancer in the U.S., it is the most expensive to treat.
Imagin Medical is developing the i/Blue™ Imaging System to help detect bladder cancer and reduce its recurrence by dramatically improving the urologist’s ability to visualize, identify and remove cancerous cells. The Company has completed development of Prototype Alpha B, an advanced combination of optical/light sensor technology, white light and near-infrared fluorescence that is expected to deliver superior images in less than 15 minutes vs. the full hour required by conventional systems. Imagin believes the time savings will increase the efficiency of the Operating Room and reduce healthcare costs by potentially enabling follow-up exams to be performed in the less expensive physician’s office.
The company’s products are based on the technology invented by Dr. Stavros Demos while a scientist at the Lawrence Livermore National Laboratory (LLNL). Dr. Demos worked in collaboration with the UC Davis Comprehensive Cancer Center and Dr. Ralph deVere White, one of the world’s leading authorities on bladder cancer, for more than five years to determine feasibility. Imagin has since licensed the technology from LLNL and moved the final stages of development to the University of Rochester where Dr. Demos has accepted a position in their Laboratory for Laser Energetics (LLE) and will continue to provide support during the completion of the product development, additional clinical evaluations and FDA submission.
As we establish the i/Blue Imaging System in the urology market, we will be completing the development of the i/Red Imaging System. This technology will potentially reach and detect cancer in other parts of the body where imaging agents cannot be practically administered.